---
title: "Hangzhou Tigermed Updates 2025 Final Dividend Terms and Tax Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284549470.md"
description: "Hangzhou Tigermed Consulting Co., Ltd. (HK:3347) has announced a final cash dividend of RMB 1.26 per 10 shares for the year ending December 31, 2025, pending shareholder approval on June 2, 2026. The dividend will be paid in HKD on July 31, 2026, with details on the exchange rate to follow. The company clarified withholding tax rates: 10% for non-resident investors and 20% for mainland individual investors. This update aims to enhance transparency regarding post-tax returns and aligns with Chinese tax regulations and Hong Kong disclosure standards. The stock currently has a Buy rating with a target price of HK$55.00."
datetime: "2026-04-29T10:23:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284549470.md)
  - [en](https://longbridge.com/en/news/284549470.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284549470.md)
---

# Hangzhou Tigermed Updates 2025 Final Dividend Terms and Tax Treatment

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An update from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) is now available.

Hangzhou Tigermed Consulting has announced an updated final cash dividend for the year ended 31 December 2025, declaring a payout of RMB 1.26 per 10 shares, subject to shareholder approval on 2 June 2026. The dividend for Hong Kong shareholders will be paid in Hong Kong dollars on 31 July 2026, with the exact HKD amount and exchange rate to be announced, while key dates such as the ex-dividend date, record date and book closure period remain pending.

The company has also clarified withholding tax arrangements for different categories of investors, including 10% withholding for non-resident enterprise and individual investors in its Shenzhen-listed A shares, and 20% withholding on dividends for mainland individual investors accessing its H shares via the Southbound Trading Link. These details provide greater transparency on post-tax returns for both domestic and cross-border shareholders, underscoring Tigermed’s efforts to align its distribution practices with Chinese tax regulations and Hong Kong market disclosure standards.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$55.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

**More about Hangzhou Tigermed Consulting Co., Ltd. Class H**

Hangzhou Tigermed Consulting Co., Ltd. is a Hong Kong-listed company providing clinical research and related consulting services to the pharmaceutical and life sciences industries. Its Class H shares trade on the Hong Kong Stock Exchange, while its A shares are listed on the Shenzhen Stock Exchange, giving it exposure to both mainland Chinese and international investors.

**Average Trading Volume:** 1,814,582

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$49.1B

### Related Stocks

- [03347.HK](https://longbridge.com/en/quote/03347.HK.md)
- [300347.CN](https://longbridge.com/en/quote/300347.CN.md)

## Related News & Research

- [Tigermed Says Probe Into Major Shareholders Will Not Hit Operations](https://longbridge.com/en/news/286261011.md)
- [Hangzhou Tigermed Unveils Up to RMB1 Billion A-Share Buyback Plan](https://longbridge.com/en/news/286280793.md)
- [Wall Street’s new tax trade chases losses in a bull market: WSJ](https://longbridge.com/en/news/286680785.md)
- [Wall Street turns to year-round tax-loss harvesting surge](https://longbridge.com/en/news/286678461.md)
- [Nuvo adds Avalara tax tools to B2B customer onboarding software](https://longbridge.com/en/news/286971059.md)